Kikuchi, S
Suzuki, R
Ohguchi, H
Yoshida, Y
Lu, D
Cottini, F
Jakubikova, J
Bianchi, G
Harada, T
Gorgun, G
Tai, Y-T
Richardson, P G
Hideshima, T
Anderson, K C
Article History
Received: 15 January 2015
Revised: 5 March 2015
Accepted: 12 March 2015
First Online: 24 March 2015
Competing interests
: PGR is a member of advisory board for Celgene, Millennium, Johnson & Johnson, Novartis and Keryx. TH is a consultant for Acetylon Pharmaceuticals. KCA is a member of advisory board for Millennium, Celgene, Gilead, Bristol Myers Squibb, and Sanofi-Aventis and is a scientific founder of Acetylon and Oncopep. The other authors declare no conflict of interest.